Citizens analyst Constantine Davides raised the price target on OptimizeRX (NASDAQ: OPRX) to $11.00 (from $9.00) while maintaining a Market Outperform rating.

The analyst commented, "We believe the stabilization of the macro backdrop, the potential return of a larger customer sometime in 2H26/2027, continued momentum around mid-tier biopharmas, the initiation of the company's DSP strategy, and the rollout of new solutions position OPRX for a return to growth in 2027. We lift our price target to $11 (8x 2026 EBITDA) from $9 (7x 2026 EBITDA), as we view a higher multiple as warranted given the more stable macro backdrop and our improved conviction in our 2027 financial estimates. OPRX recently traded at 7x our NTM EBITDA estimate, below its two-year average of 11.5x."